Eli Lilly: Expanding With a Billion-Dollar Project in Germany

Eli Lilly is one of the most traditional pharmaceutical companies in the USA and has increasingly focused in recent years on high-growth areas such as oncology, diabetes, and especially Alzheimer's therapies. With the active ingredient Donanemab, a potential blockbuster for the treatment of Alzheimer's disease is on the verge of approval, opening up new revenue opportunities for the company. Additionally, Lilly is benefiting from the success of its obesity drug Zepbound, which has become a revenue driver and is in direct competition with products...